25C-NBOMe: Difference between revisions

(Text replacement - "AMS" to "altered mental status")
No edit summary
Line 1: Line 1:
[[File:25C-NBOMe.png|thumbnail|25C-NBOMe]]
''Although this article specifically addresses 25C-NBOMe, there are also 25I- and 25B- versions of the compound''
Although this article specifically addresses 25C-NBOMe, there are also 25I- and 25B- versions of the compound all of which are Schedule I controlled substances in the United States.  They were first synthesized in Germany by Ralf Heim in 2004<ref>Heim R. “Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur”. :Entwicklung eines neuen Struktur-Wirkungskonzepts. Berlin, Freie University, Dissertation, 2003</ref>
 
==Background==
==Background==
*2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
*2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
*Other names: NBOMe-2C-C, Boom, C-Boom, Cimbi-82, Pandora, N-bomb, Holland film, Dime
*Other names: NBOMe-2C-C, Boom, C-Boom, Cimbi-82, Pandora, N-bomb, Holland film, Dime
*Potent partial agonist of 5-HT2A receptor<ref name="pharm">Bersani FS, Corazza O, Albano G, et al. 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. Biomed Res Int. 2014;2014:734749.</ref>
*Potent partial agonist of 5-HT2A receptor<ref name="pharm">Bersani FS, Corazza O, Albano G, et al. 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. Biomed Res Int. 2014;2014:734749.</ref>
*Member of new class of toxic phenethylamine derivatives (NBOMe) with similar effects to [[LSD]] which is commonly ingested ingested orally or sublingually; can also be ingested nasally, parenterally, vaginally, rectally.
*First synthesized in Germany by Ralf Heim in 2004<ref>Heim R. “Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur”. :Entwicklung eines neuen Struktur-Wirkungskonzepts. Berlin, Freie University, Dissertation, 2003</ref>
*Member of new class of toxic phenethylamine derivatives (NBOMe) with similar effects to [[LSD]]
*Commonly ingested orally or sublingually; can also be taken nasally, parenterally, vaginally, rectally.
*Dose of 50-200 micrograms causes hallucinogenic effects<ref name="pharm"></ref>
*Dose of 50-200 micrograms causes hallucinogenic effects<ref name="pharm"></ref>
*Onset 0-15 mins, peak 30-90 mins, total duration 4-10 hours<ref name="pharm"></ref>
*Onset 0-15 mins, peak 30-90 mins, total duration 4-10 hours<ref name="pharm"></ref>
*Case reports of ingestions have included overdose symptoms of grand mal seizures and purpuric rash and mydriasis with 25'''B'''-NBOMe variant<ref>Poklis JL. et al. Determination of 4 bromo 2,5 dimethoxy N [2 methoxyphenyl) methyl] benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug Test Anal. 2004;6:764-9</ref>
*Case reports of ingestions have included overdose symptoms of grand mal seizures and purpuric rash and mydriasis with 25'''B'''-NBOMe variant<ref>Poklis JL. et al. Determination of 4 bromo 2,5 dimethoxy N [2 methoxyphenyl) methyl] benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug Test Anal. 2004;6:764-9</ref>
*The 25I- version of the drug has symptoms described as tachycardia, hallucinations, hypertension, and seizures and agitation.<ref>Poklis J. Devers KG et al. Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)methyl] ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. Forensic Sci Int. 2014;234:e14-e20</ref>


*The 25I- version of the drug has symptoms described as tachycardia, hallucinations, hypertension, and seizures and agitation.<ref>Poklis J. Devers KG et al. Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)methyl] ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. Forensic Sci Int. 2014;234:e14-e20</ref>
[[File:25C-NBOMe.png|thumb|25C-NBOMe]]


==Clinical Features==
==Clinical Features==
Line 34: Line 36:
*[[Metabolic Acidosis]]
*[[Metabolic Acidosis]]


==Workup==
==Evaluation==
{{Hallucinogen workup}}
{{Hallucinogen workup}}


Line 45: Line 47:
*'''[[Seizure]]'''
*'''[[Seizure]]'''
**[[Benzodiazepines]]
**[[Benzodiazepines]]
**manage airway as indicated
*[[Hyperthermia]]:
*[[Hyperthermia]]:
**ice packs, cold IVF
**Passive cooling measures


==Disposition==
==Disposition==
*Admit for monitoring on all patients with continuing agitation requiring escalating doses of sedation
*Admit for monitoring on all patients with continuing agitation requiring escalating doses of sedation
*Admit for fluids in patient with monitoring
*Consider discharge if complete resolution of symptoms
*Patient with full resolution of symptoms can be discharged from the emergency department


==See Also==
==See Also==
*[[LSD]]
*[[Lysergic acid diethylamide (LSD)]]
*[[Ecstasy (MDMA)]]
*[[Ecstasy (MDMA) toxicity]]
*[[Hallucinations]]
*[[Hallucinations]]
*[[Hallucinogens]]
*[[Hallucinogens]]

Revision as of 03:42, 9 July 2017

Although this article specifically addresses 25C-NBOMe, there are also 25I- and 25B- versions of the compound

Background

  • 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
  • Other names: NBOMe-2C-C, Boom, C-Boom, Cimbi-82, Pandora, N-bomb, Holland film, Dime
  • Potent partial agonist of 5-HT2A receptor[1]
  • First synthesized in Germany by Ralf Heim in 2004[2]
  • Member of new class of toxic phenethylamine derivatives (NBOMe) with similar effects to LSD
  • Commonly ingested orally or sublingually; can also be taken nasally, parenterally, vaginally, rectally.
  • Dose of 50-200 micrograms causes hallucinogenic effects[1]
  • Onset 0-15 mins, peak 30-90 mins, total duration 4-10 hours[1]
  • Case reports of ingestions have included overdose symptoms of grand mal seizures and purpuric rash and mydriasis with 25B-NBOMe variant[3]
  • The 25I- version of the drug has symptoms described as tachycardia, hallucinations, hypertension, and seizures and agitation.[4]
25C-NBOMe

Clinical Features

Evaluation

Hallucination workup

Management

Disposition

  • Admit for monitoring on all patients with continuing agitation requiring escalating doses of sedation
  • Consider discharge if complete resolution of symptoms

See Also

References

  1. ↑ 1.0 1.1 1.2 Bersani FS, Corazza O, Albano G, et al. 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. Biomed Res Int. 2014;2014:734749.
  2. ↑ Heim R. “Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur”. :Entwicklung eines neuen Struktur-Wirkungskonzepts. Berlin, Freie University, Dissertation, 2003
  3. ↑ Poklis JL. et al. Determination of 4 bromo 2,5 dimethoxy N [2 methoxyphenyl) methyl] benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug Test Anal. 2004;6:764-9
  4. ↑ Poklis J. Devers KG et al. Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)methyl] ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. Forensic Sci Int. 2014;234:e14-e20
  5. ↑ Boyer EW, Shannon M. The serotonin syndrome. NEJM. 2005;352:1112-20
Retrieved from "https://www.wikem.org/w/index.php?title=25C-NBOMe&oldid=146302"